Evolus, Inc. (EOLS), a performance beauty company, has unveiled its new campaign "Drop the F Word" to challenge outdated perceptions of aesthetic injectables ahead of the commercial launch of Evolysse.
This new line of hyaluronic acid - HA gels is designed to treat moderate to severe facial wrinkles while delivering natural-looking, long-lasting results.
The campaign addresses rising consumer "filler fatigue," as many now associate the word "filler" with artificial or overdone results. Based on extensive consumer research, Evolus is removing the term "filler" from its language, introducing Evolysse as a modern solution that reflects evolving beauty standards.
CEO David Moatazedi emphasized the need to move beyond the term "filler" and focus on personalized, authentic beauty results. Backed by Cold-X technology, Evolysse is the first major HA innovation in over a decade and is designed to preserve the HA molecule's natural structure for more refined outcomes.
Evolus is using this launch to encourage the industry to reframe how aesthetic treatments are discussed, aiming to foster a more informed and confidence-driven beauty experience.
EOLS is currently trading at $10.38 or 1.47% higher on the Nasdaq Global Market.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.